Cancer treatment has long faced a challenging trade-off: therapies strong enough to eliminate tumors often cause severe side effects. One promising solution involves cytokines, natural proteins that ...

ASTRAZENECA is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with ...

At just 52 years old, a woman has been diagnosed with Stage 4 lung cancer. A non-smoker who had worked full-time since age 22, she now faces a terminal illness while trying to support her husband and ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A study shows for the first time the relationship between this disease and the damage caused to DNA by breathing pollution.

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Swedish Match, a subsidiary of Philip Morris International, makes the ZYN pouches. The FDA's approval noted the patches posed ...

BrightSpring Health Services Inc. (NASDAQ:BTSG) is a home and community-based healthcare services platform in the US that ...

Lung cancer among never-smokers is rising worldwide. In one U.S. study of 12,000 lung cancer patients, the share of people who didn’t smoke rose from 8 to 15 percent over twenty years.

Australia’s new lung cancer screen program further disadvantages Aboriginal and Torres Strait Islander peoples, who are ...

Vaping, Juuling, cloud chasing – we have all most likely heard of electronic cigarettes or vapes. With so many new terms and devices being pushed to market, it can feel hard to keep track of the ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...